Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03358355 · ClinicalTrials.gov registry record · Phase 1
Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03358355 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 9 participants.
The verdict
NCT03358355, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).
Interventions
- DRUG unacelyated ghrelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-06-07 |
| Est. Completion | 2017-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03358355
The ClinicalTrials.gov registry entry for NCT03358355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which unacelyated ghrelin is the first listed.
NCT03358355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03358355 about?
NCT03358355 is a clinical study titled "Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial". The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).
What is the current status of trial NCT03358355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-06-07. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03358355?
The interventions under investigation include: unacelyated ghrelin (DRUG).
Who is sponsoring clinical trial NCT03358355?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.